Skip to main content
TipRanks
Go Ultimate75% OFF

Sangamo Therapeutics (SGMOQ) Stock Price & Analysis

2,675 Followers

SGMOQ Stock Chart & Stats

$0.11-$0.01(-7.69%)
At close: 4:00 PM EST
$0.1$0.125$0.15Aug 24Sep 8Sep 21Oct 5Oct 19Nov 2Nov 16
Day’s Range
$0.11 - $0.12
52-Week Range
$0.01 - $0.60
Previous Close
$0.12
Volume
N/A
Average Volume (3M)
1.33M
Market Cap
$45.12M
Enterprise Value
$87.94M
Total Cash (Recent Filing)
$27.59M
Total Debt (Recent Filing)
$19.33M
Price to Earnings (P/E)
―
Beta
2.36
Next Earnings
Feb 24, 2027 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Genomic Medicine Focus

A focused genomic-medicine platform gives Sangamo exposure to therapies addressing serious diseases and preserves specialized scientific capabilities. Its research-led model can support substantial long-term value creation if investigational programs achieve clinical and regulatory success.

Fabry Asset Monetization

Selling ST-920 to PTC converted a major pipeline asset into substantial immediate cash while retaining potential milestone upside. Although proceeds are subject to bankruptcy priorities, the transaction demonstrates that parts of Sangamo’s technology portfolio retain strategic value.

Strong Gross Margin

The high gross margin indicates that Sangamo’s underlying partnered and development-related activities can generate meaningful contribution after direct costs. If revenue-bearing programs return, this gross-profit structure could provide operating leverage, even though current expenses remain too high.

Bears Say

Chapter 11 Restructuring

Chapter 11 places the business under court-supervised restructuring and creates substantial uncertainty around asset ownership, capital allocation, and the company’s future operating structure. Delisting further reduces institutional access and signals that equity holders face an unusually weak position.

Persistent Cash Burn

Sustained operating and free-cash-flow deficits show that the business has not funded itself through operations and continues to consume capital. This weak cash-generation profile limits investment capacity and increases dependence on asset sales, financing, or restructuring outcomes.

Declining Revenue And Negative Equity

Falling revenue reduces the scale available to absorb Sangamo’s cost base, while negative equity reflects a materially weakened financial position. Together, these conditions constrain strategic flexibility and heighten the risk that future value is directed toward creditors or new capital providers.

Sangamo Therapeutics News

SGMOQ FAQ

What was Sangamo Therapeutics’s price range in the past 12 months?
Sangamo Therapeutics lowest stock price was $0.01 and its highest was $0.60 in the past 12 months.
What is Sangamo Therapeutics’s market cap?
Sangamo Therapeutics’s market cap is $45.12M.
When is Sangamo Therapeutics’s upcoming earnings report date?
Sangamo Therapeutics’s next earnings report is estimated for Aug 11, 2026 (not yet confirmed), which is 98 days ago.
How were Sangamo Therapeutics’s earnings last quarter?
Sangamo Therapeutics released its earnings results on May 14, 2026. The company reported -$0.08 earnings per share for the quarter, missing the consensus estimate of $0.005 by -$0.085.
Is Sangamo Therapeutics overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Sangamo Therapeutics pay dividends?
Sangamo Therapeutics does not currently pay dividends.
What is Sangamo Therapeutics’s EPS estimate?
Sangamo Therapeutics’s EPS estimate is -0.07.
How many shares outstanding does Sangamo Therapeutics have?
Sangamo Therapeutics has 414,288,850 shares outstanding.
What happened to Sangamo Therapeutics’s price movement after its last earnings report?
Sangamo Therapeutics reported an EPS of -$0.08 in its last earnings report, missing expectations of $0.005. Following the earnings report the stock price went up 0.847%.
Which hedge fund is a major shareholder of Sangamo Therapeutics?
Hedge funds hold Sangamo Therapeutics shares: the largest hedge-fund position in Sangamo Therapeutics is 65,742,405 shares, and hedge funds decreased their holdings by 4.5M shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology